1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014

Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 26 pages

Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014’, provides an overview of the Eagle Pharmaceuticals Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eagle Pharmaceuticals Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Eagle Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Eagle Pharmaceuticals Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Eagle Pharmaceuticals Inc.’s pipeline products

Reasons to buy

- Evaluate Eagle Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Eagle Pharmaceuticals Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Eagle Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Eagle Pharmaceuticals Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eagle Pharmaceuticals Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Eagle Pharmaceuticals Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014
Table of Contents

Eagle Pharmaceuticals Inc. Snapshot 4
Eagle Pharmaceuticals Inc. Overview 4
Key Information 4
Key Facts 4
Eagle Pharmaceuticals Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Eagle Pharmaceuticals Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Eagle Pharmaceuticals Inc. - Pipeline Products Glance 11
Eagle Pharmaceuticals Inc. - Late Stage Pipeline Products 11
Pre-Registration Products/Combination Treatment Modalities 11
Eagle Pharmaceuticals Inc. - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Eagle Pharmaceuticals Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Eagle Pharmaceuticals Inc. - Drug Profiles 14
bendamustine hydrochloride RTD 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
bendamustine hydrochloride SI 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
EP-4104 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
bivalirudin 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
pemetrexed disodium 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Eagle Pharmaceuticals Inc. - Pipeline Analysis 19
Eagle Pharmaceuticals Inc. - Pipeline Products by Target 19
Eagle Pharmaceuticals Inc. - Pipeline Products by Route of Administration 20
Eagle Pharmaceuticals Inc. - Pipeline Products by Molecule Type 21
Eagle Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action 22
Eagle Pharmaceuticals Inc. - Recent Pipeline Updates 23
Eagle Pharmaceuticals Inc. - Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26

List of Tables

Eagle Pharmaceuticals Inc., Key Information 4
Eagle Pharmaceuticals Inc., Key Facts 4
Eagle Pharmaceuticals Inc. - Pipeline by Indication, 2014 6
Eagle Pharmaceuticals Inc. - Pipeline by Stage of Development, 2014 7
Eagle Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2014 8
Eagle Pharmaceuticals Inc. - Partnered Products in Pipeline, 2014 9
Eagle Pharmaceuticals Inc. - Partnered Products/ Combination Treatment Modalities, 2014 10
Eagle Pharmaceuticals Inc. - Pre-Registration, 2014 11
Eagle Pharmaceuticals Inc. - Phase I, 2014 12
Eagle Pharmaceuticals Inc. - Preclinical, 2014 13
Eagle Pharmaceuticals Inc. - Pipeline by Target, 2014 19
Eagle Pharmaceuticals Inc. - Pipeline by Route of Administration, 2014 20
Eagle Pharmaceuticals Inc. - Pipeline by Molecule Type, 2014 21
Eagle Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2014 22
Eagle Pharmaceuticals Inc. - Recent Pipeline Updates, 2014 23

List of Figures

Eagle Pharmaceuticals Inc. - Pipeline by Top 10 Indication, 2014 6
Eagle Pharmaceuticals Inc. - Pipeline by Stage of Development, 2014 7
Eagle Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2014 8
Eagle Pharmaceuticals Inc. - Pipeline by Top 10 Target, 2014 19
Eagle Pharmaceuticals Inc. - Pipeline by Top 10 Route of Administration, 2014 20
Eagle Pharmaceuticals Inc. - Pipeline by Top 10 Molecule Type, 2014 21
Eagle Pharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.